The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy

Brian J. Linder, Igor Frank, John C. Cheville, Matthew K. Tollefson, R. Houston Thompson, Robert F. Tarrell, Prabin Thapa, Stephen A. Boorjian

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Background: While the receipt of a perioperative blood transfusion (PBT) has been associated with an increased risk of mortality for a number of malignancies, the relationship between PBT and survival following radical cystectomy (RC) for bladder cancer (BCa) has not been well established. Objective: To evaluate the association of PBT with disease recurrence and mortality following RC. Design, setting, and participants: We identified 2060 patients who underwent RC at the Mayo Clinic between 1980 and 2005. PBT was defined as transfusion of allogenic red blood cells during RC or postoperative hospitalization. Outcome measurements and statistical analysis: Survival was estimated using the Kaplan-Meier method and was compared with the log-rank test. Cox proportional hazard regression models were used to evaluate the association of PBT with outcome, controlling for clinicopathologic variables. Results and limitations: A total of 1279 patients (62%) received PBT. The median number of units transfused was 2 (interquartile range [IQR]: 2-4). Patients receiving PBT were significantly older (median: 69 yr vs 66 yr; p < 0.0001), had a worse Eastern Cooperative Oncology Group performance status (p < 0.0001), and were more likely to have muscle-invasive tumors (56% vs 49%; p = 0.004). Median postoperative follow-up was 10.9 yr (IQR: 7.9-15.7). Receipt of PBT was associated with significantly worse 5-yr recurrence-free survival (58% vs 64%; p = 0.01), cancer-specific survival (59% vs 72%; p < 0.001), and overall survival (45% vs 63%; p < 0.001). On multivariate analyses, PBT remained associated with significantly increased risks of postoperative tumor recurrence (hazard ratio [HR]: 1.20; p = 0.04), death from BCa (HR: 1.31; p = 0.003), and all-cause mortality (HR: 1.27; p = 0.0002). Among patients who received PBT, an increasing number of units transfused was independently associated with increased cancer-specific mortality (HR: 1.07; p < 0.0001) and all-cause mortality (HR: 1.05; p < 0.0001). Limitations include selection bias and lack of standardized transfusion criteria. Conclusions: We found that PBT is associated with significantly increased risks of cancer recurrence and mortality following RC. While external validation is required, continued efforts to reduce the use of blood products in these patients are warranted.

Original languageEnglish (US)
Pages (from-to)839-845
Number of pages7
JournalEuropean Urology
Volume63
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Cystectomy
Blood Transfusion
Recurrence
Survival
Neoplasms
Mortality
Urinary Bladder Neoplasms
Erythrocyte Transfusion
Selection Bias
Survival Analysis
Proportional Hazards Models
Hospitalization
Multivariate Analysis
Muscles

Keywords

  • Bladder cancer
  • Radical cystectomy
  • Transfusion
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Linder, B. J., Frank, I., Cheville, J. C., Tollefson, M. K., Thompson, R. H., Tarrell, R. F., ... Boorjian, S. A. (2013). The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. European Urology, 63(5), 839-845. https://doi.org/10.1016/j.eururo.2013.01.004

The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. / Linder, Brian J.; Frank, Igor; Cheville, John C.; Tollefson, Matthew K.; Thompson, R. Houston; Tarrell, Robert F.; Thapa, Prabin; Boorjian, Stephen A.

In: European Urology, Vol. 63, No. 5, 05.2013, p. 839-845.

Research output: Contribution to journalArticle

Linder, BJ, Frank, I, Cheville, JC, Tollefson, MK, Thompson, RH, Tarrell, RF, Thapa, P & Boorjian, SA 2013, 'The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy', European Urology, vol. 63, no. 5, pp. 839-845. https://doi.org/10.1016/j.eururo.2013.01.004
Linder, Brian J. ; Frank, Igor ; Cheville, John C. ; Tollefson, Matthew K. ; Thompson, R. Houston ; Tarrell, Robert F. ; Thapa, Prabin ; Boorjian, Stephen A. / The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. In: European Urology. 2013 ; Vol. 63, No. 5. pp. 839-845.
@article{fc240888b54a44c5b3abd1af1210093c,
title = "The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy",
abstract = "Background: While the receipt of a perioperative blood transfusion (PBT) has been associated with an increased risk of mortality for a number of malignancies, the relationship between PBT and survival following radical cystectomy (RC) for bladder cancer (BCa) has not been well established. Objective: To evaluate the association of PBT with disease recurrence and mortality following RC. Design, setting, and participants: We identified 2060 patients who underwent RC at the Mayo Clinic between 1980 and 2005. PBT was defined as transfusion of allogenic red blood cells during RC or postoperative hospitalization. Outcome measurements and statistical analysis: Survival was estimated using the Kaplan-Meier method and was compared with the log-rank test. Cox proportional hazard regression models were used to evaluate the association of PBT with outcome, controlling for clinicopathologic variables. Results and limitations: A total of 1279 patients (62{\%}) received PBT. The median number of units transfused was 2 (interquartile range [IQR]: 2-4). Patients receiving PBT were significantly older (median: 69 yr vs 66 yr; p < 0.0001), had a worse Eastern Cooperative Oncology Group performance status (p < 0.0001), and were more likely to have muscle-invasive tumors (56{\%} vs 49{\%}; p = 0.004). Median postoperative follow-up was 10.9 yr (IQR: 7.9-15.7). Receipt of PBT was associated with significantly worse 5-yr recurrence-free survival (58{\%} vs 64{\%}; p = 0.01), cancer-specific survival (59{\%} vs 72{\%}; p < 0.001), and overall survival (45{\%} vs 63{\%}; p < 0.001). On multivariate analyses, PBT remained associated with significantly increased risks of postoperative tumor recurrence (hazard ratio [HR]: 1.20; p = 0.04), death from BCa (HR: 1.31; p = 0.003), and all-cause mortality (HR: 1.27; p = 0.0002). Among patients who received PBT, an increasing number of units transfused was independently associated with increased cancer-specific mortality (HR: 1.07; p < 0.0001) and all-cause mortality (HR: 1.05; p < 0.0001). Limitations include selection bias and lack of standardized transfusion criteria. Conclusions: We found that PBT is associated with significantly increased risks of cancer recurrence and mortality following RC. While external validation is required, continued efforts to reduce the use of blood products in these patients are warranted.",
keywords = "Bladder cancer, Radical cystectomy, Transfusion, Urothelial carcinoma",
author = "Linder, {Brian J.} and Igor Frank and Cheville, {John C.} and Tollefson, {Matthew K.} and Thompson, {R. Houston} and Tarrell, {Robert F.} and Prabin Thapa and Boorjian, {Stephen A.}",
year = "2013",
month = "5",
doi = "10.1016/j.eururo.2013.01.004",
language = "English (US)",
volume = "63",
pages = "839--845",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy

AU - Linder, Brian J.

AU - Frank, Igor

AU - Cheville, John C.

AU - Tollefson, Matthew K.

AU - Thompson, R. Houston

AU - Tarrell, Robert F.

AU - Thapa, Prabin

AU - Boorjian, Stephen A.

PY - 2013/5

Y1 - 2013/5

N2 - Background: While the receipt of a perioperative blood transfusion (PBT) has been associated with an increased risk of mortality for a number of malignancies, the relationship between PBT and survival following radical cystectomy (RC) for bladder cancer (BCa) has not been well established. Objective: To evaluate the association of PBT with disease recurrence and mortality following RC. Design, setting, and participants: We identified 2060 patients who underwent RC at the Mayo Clinic between 1980 and 2005. PBT was defined as transfusion of allogenic red blood cells during RC or postoperative hospitalization. Outcome measurements and statistical analysis: Survival was estimated using the Kaplan-Meier method and was compared with the log-rank test. Cox proportional hazard regression models were used to evaluate the association of PBT with outcome, controlling for clinicopathologic variables. Results and limitations: A total of 1279 patients (62%) received PBT. The median number of units transfused was 2 (interquartile range [IQR]: 2-4). Patients receiving PBT were significantly older (median: 69 yr vs 66 yr; p < 0.0001), had a worse Eastern Cooperative Oncology Group performance status (p < 0.0001), and were more likely to have muscle-invasive tumors (56% vs 49%; p = 0.004). Median postoperative follow-up was 10.9 yr (IQR: 7.9-15.7). Receipt of PBT was associated with significantly worse 5-yr recurrence-free survival (58% vs 64%; p = 0.01), cancer-specific survival (59% vs 72%; p < 0.001), and overall survival (45% vs 63%; p < 0.001). On multivariate analyses, PBT remained associated with significantly increased risks of postoperative tumor recurrence (hazard ratio [HR]: 1.20; p = 0.04), death from BCa (HR: 1.31; p = 0.003), and all-cause mortality (HR: 1.27; p = 0.0002). Among patients who received PBT, an increasing number of units transfused was independently associated with increased cancer-specific mortality (HR: 1.07; p < 0.0001) and all-cause mortality (HR: 1.05; p < 0.0001). Limitations include selection bias and lack of standardized transfusion criteria. Conclusions: We found that PBT is associated with significantly increased risks of cancer recurrence and mortality following RC. While external validation is required, continued efforts to reduce the use of blood products in these patients are warranted.

AB - Background: While the receipt of a perioperative blood transfusion (PBT) has been associated with an increased risk of mortality for a number of malignancies, the relationship between PBT and survival following radical cystectomy (RC) for bladder cancer (BCa) has not been well established. Objective: To evaluate the association of PBT with disease recurrence and mortality following RC. Design, setting, and participants: We identified 2060 patients who underwent RC at the Mayo Clinic between 1980 and 2005. PBT was defined as transfusion of allogenic red blood cells during RC or postoperative hospitalization. Outcome measurements and statistical analysis: Survival was estimated using the Kaplan-Meier method and was compared with the log-rank test. Cox proportional hazard regression models were used to evaluate the association of PBT with outcome, controlling for clinicopathologic variables. Results and limitations: A total of 1279 patients (62%) received PBT. The median number of units transfused was 2 (interquartile range [IQR]: 2-4). Patients receiving PBT were significantly older (median: 69 yr vs 66 yr; p < 0.0001), had a worse Eastern Cooperative Oncology Group performance status (p < 0.0001), and were more likely to have muscle-invasive tumors (56% vs 49%; p = 0.004). Median postoperative follow-up was 10.9 yr (IQR: 7.9-15.7). Receipt of PBT was associated with significantly worse 5-yr recurrence-free survival (58% vs 64%; p = 0.01), cancer-specific survival (59% vs 72%; p < 0.001), and overall survival (45% vs 63%; p < 0.001). On multivariate analyses, PBT remained associated with significantly increased risks of postoperative tumor recurrence (hazard ratio [HR]: 1.20; p = 0.04), death from BCa (HR: 1.31; p = 0.003), and all-cause mortality (HR: 1.27; p = 0.0002). Among patients who received PBT, an increasing number of units transfused was independently associated with increased cancer-specific mortality (HR: 1.07; p < 0.0001) and all-cause mortality (HR: 1.05; p < 0.0001). Limitations include selection bias and lack of standardized transfusion criteria. Conclusions: We found that PBT is associated with significantly increased risks of cancer recurrence and mortality following RC. While external validation is required, continued efforts to reduce the use of blood products in these patients are warranted.

KW - Bladder cancer

KW - Radical cystectomy

KW - Transfusion

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84876023963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876023963&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2013.01.004

DO - 10.1016/j.eururo.2013.01.004

M3 - Article

C2 - 23332883

AN - SCOPUS:84876023963

VL - 63

SP - 839

EP - 845

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -